Investors are seeing little good news in the latest experimental drug data from the biotechnology industry.
On Nov. 3, after results from several clinical trials were released ahead of the upcoming American Society of Hematology, or ASH, meeting in San Diego, Spark Therapeutics Inc., Bluebird Bio Inc., and Trillium Therapeutics Inc. all plunged. Their drops led to an as much as 1.7 percent decline in the Nasdaq Biotechnology Index, which is now down 26 percent this year.
“There are two kinds of news in biotech these days, there’s bad news and worse news,” Eric Schmidt, an analyst at Cowen & ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.